These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24297342)

  • 1. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
    Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X
    Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RASAL1 attenuates gastric carcinogenesis in nude mice by blocking RAS/ERK signaling.
    Chen H; Zhao JY; Qian XC; Cheng ZY; Liu Y; Wang Z
    Asian Pac J Cancer Prev; 2015; 16(3):1077-82. PubMed ID: 25735335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raf/MEK/ERK can regulate cellular levels of LC3B and SQSTM1/p62 at expression levels.
    Kim JH; Hong SK; Wu PK; Richards AL; Jackson WT; Park JI
    Exp Cell Res; 2014 Oct; 327(2):340-52. PubMed ID: 25128814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical role of SHP2 (PTPN11) signaling in germinal center-derived lymphoma.
    Jiang X; Guo H; Wu J; He Q; Li Y; Wang M; Pan H; Li W; Wang J; Wang Q; Shen J; Ke Y; Zhou R
    Haematologica; 2014 Dec; 99(12):1834-45. PubMed ID: 25193962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.
    Riverso M; Montagnani V; Stecca B
    Oncogene; 2017 Jun; 36(23):3322-3333. PubMed ID: 28068326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of lipid phosphate phosphatase activity by VPC32183 suppresses the ability of diacylglycerol pyrophosphate to activate ERK(1/2) MAP kinases.
    Violet PC; Billon-Denis E; Robin P
    Biochim Biophys Acta; 2012 Nov; 1821(11):1394-405. PubMed ID: 22820196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway.
    Wakasaki T; Masuda M; Niiro H; Jabbarzadeh-Tabrizi S; Noda K; Taniyama T; Komune S; Akashi K
    Neoplasia; 2010 Oct; 12(10):789-96. PubMed ID: 20927317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival.
    Hu Y; Mintz A; Shah SR; Quinones-Hinojosa A; Hsu W
    Carcinogenesis; 2014 Jul; 35(7):1491-9. PubMed ID: 24445144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of IRF1-dependent anticancer effects by MEK inhibition in human cancer cells.
    AbuSara N; Razavi S; Derwish L; Komatsu Y; Licursi M; Hirasawa K
    Cancer Lett; 2015 Feb; 357(2):575-81. PubMed ID: 25497010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
    Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S
    Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
    Han T; Xiang DM; Sun W; Liu N; Sun HL; Wen W; Shen WF; Wang RY; Chen C; Wang X; Cheng Z; Li HY; Wu MC; Cong WM; Feng GS; Ding J; Wang HY
    J Hepatol; 2015 Sep; 63(3):651-60. PubMed ID: 25865556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway.
    Dance M; Montagner A; Salles JP; Yart A; Raynal P
    Cell Signal; 2008 Mar; 20(3):453-9. PubMed ID: 17993263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
    Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
    Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma.
    Jiang C; Hu F; Tai Y; Du J; Mao B; Yuan Z; Wang Y; Wei L
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):637-46. PubMed ID: 22228034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-talk between endoplasmic reticulum (ER) stress and the MEK/ERK pathway potentiates apoptosis in human triple negative breast carcinoma cells: role of a dihydropyrimidone, nifetepimine.
    Ghosh S; Adhikary A; Chakraborty S; Bhattacharjee P; Mazumder M; Putatunda S; Gorain M; Chakraborty A; Kundu GC; Das T; Sen PC
    J Biol Chem; 2015 Feb; 290(7):3936-49. PubMed ID: 25527500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma.
    Chen L; Shi Y; Jiang CY; Wei LX; Wang YL; Dai GH
    Eur J Surg Oncol; 2011 Jun; 37(6):513-20. PubMed ID: 21324414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.